Chlorambucil in chronic lymphocytic leukemia: Mechanism of action

Leukemia and Lymphoma

Volumn 23, Issue 3-4, 1996, Pages 187-201

  Begleiter, Asher ^a   Mowat, Michael ^a   Israels, Lyonel G ^a   Johnston, James B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chlorambucil; Chronic lymphocytic leukemia; Mechanisms; Resistance; Sensitivity

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; DNA FRAGMENT; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ALKYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA CROSS LINKING; DNA REPAIR; DRUG BINDING; DRUG DETOXIFICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030460338     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609054821     Document Type: Review

References (94)

1. Montserrat, E. and Rozman, C. (1993) Chronic lymphocytic leukaemia treatment. Blood Rev. 7, 164-175.
2. Foon, K. A., Rai, K. R. and Gale, R P. (1990) Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med 113, 525-539.
3. Rai, K. R., Sawitsky, A., Cronkite, E P., Chanana, A. D., Levy, R. N and Pasternack, B S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234.
4. Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, F., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M. T., Monconduit, M., Belabbes, S. and Gremy, F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206.
5. Montserrat, E., Sanchez-Bisono, J., Vinolas, N. and Rozman, C. (1986) Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br. J. Haematol. 62, 567-575.
6. Vallespi, T., Montserrat, E. and Sanz, M. A. (1991) Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. Br. J. Haematol. 77, 478-485.
7. Pangalis, G. A., Rousso, P A., Kittas, C., Kokkinou, S. and Fessas, P. (1987) B-chronic lymphocytic leukemia: prognostic implication of bone marrow histology in 120 patients. Experience from a single hematology unit Cancer 59, 767-771.
8. Juliusson, G and Gahrton, G. (1990) Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet. Cytogenet. 45, 143-160.
9. Schena, M., Larsson, L. G., Gottardi, D., Gaidano, G., Carlsson, M., Nilsson, K. and Caligaris Cappio, F. (1992) Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79, 2981-2989.
10. Korsmeyer, S. J. (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80, 879-886.
11. Juliusson, G., Gahrton, G., Einhorn, S., Liu, Y., Oscier, D. G. and Chapman, R. (1993) Chromosome abnormalities and RB1 gene deletions in chronic lymphocytic leukemia. Blood 82, 1938-1939.
12. Huguley, C. M. J. (1977) Treatment of chronic lymphocytic leukemia. Cancer Treat. Rev. 4, 261-273.
13. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E. J. and McCredie, K. B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74, 19-25.
14. Juliusson, G. and Liliemark, J. (1993) High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 11, 679-689.
15. Grever, M. R., Leiby, J. M., Kraut, E. H., Wilson, H. E., Neidhart, J. A., Wall, R. L. and Balcerzak, S. P. (1985) Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 3, 1196-1201.
16. Keating, M. J. (1993) Chemotherapy of chronic lymphocytic leukemia. In Chronic lymphocytic leukemia: Scientific advances and clinical development, edited by B. D. Cheson, New York: Marcel Dekker, Inc. (pp. 297).
17. Karnofsky, D. A (1958) Summary of results obtained with nitrogen mustard in the treatment of neoplastic disease. Ann N. Y. Acad. Sci. 68, 899-914.
18. Ross, W C J. (1962) Biological alkylating agents. London: Butterworth & Co Ltd. (pp. 122)
19. Israels, L. G., Galton, D. A. G., Till, M. and Wiltshaw, E. (1958) Clinical evaluation of CB 1348 in malignant lymphoma and related diseases. Ann. N. Y Acad. Sci. 68, 915-925.
20. Stacey, K. A., Cobb, M., Cousens, S. F. and Alexander, P. (1958) The reactions of the "radiomimetic" alkylating agents with macromolecules in vitro. Ann. N. Y. Acad Sci. 68, 682-730
21. Ross, W C. J. (1962) Biological alkylating agents. London: Butterworth & Co. Ltd. (pp. 32-50).
22. Ross, W C J. (1962) Biological alkylating agents. London: Butterworth & Co. Ltd (pp. 64-92)
23. Ross, W. C. J. (1962) Biological alkylating agents. London: Butterworth & Co Ltd. (p. 98).
24. Hill, B. T (1972) Studies on the transport and cellular distribution of chlorambucil in the Yoshida ascites sarcoma. Biochem Pharmacol 21, 495-502.
25. Begleiter, A and Goldenberg, G J. (1983) Uptake and decomposition of chlorambucil by L5178Y lymphoblasts in vitro. Biochem. Pharmacol. 32, 535-539.
26. Farmer, P. B. (1987) Metabolism and reactions of alkylating agents Pharmacol Therap. 35, 301-358
27. Panasci, L., Henderson, D., Torres-Garcia, S. J., Skalski, V., Caplan, S. and Hutchinson, M. (1988) Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res. 48, 1972-1976.
28. Harrap, K. R. and Hill, B. T. (1970) The selectivity of action of alkylating agents and drug resistance. III. The uptake and degradation of alkylating agents by Yoshida ascites sarcoma cells in vitro. Biochem. Pharmacol. 19, 209-217.
29. Harrap K. R. and Gascoigne E. W. (1976) The interaction of bifunctional alkylating agents with the DNA of tumor cells. Eur J. Cancer 12, 53-59
30. Robson, C N., Lewis, A D., Wolf, C. R , Hayes, J. D., Hall, A., Proctor, S. J., Harris, A. L. and Hickson, I. D. (1987) Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity. Cancer Res. 47, 6022-6027.
31. Robson, C. N , Alexander, J., Harris, A. L. and Hickson, I D. (1986) Isolation and characterization of a Chinese hamster ovary cell line resistant to bifunctional nitrogen mustards. Cancer Res. 46, 6290-6294.
32. Lewis, A. D , Hickson, I. D., Robson, C N., Harris, A. L., Hayes, J. D., Griffiths, S. A , Manson, M. M., Hall, A. E., Moss, J. E. and Wolf, C. R. (1988) Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc. Natl. Acad. Sci. U.S.A. 85, 8511-8515.
33. Arrick, B. A. and Nathan, C. F. (1984) Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 44, 4224-4232.
34. Sies, H. and Ketterer, B. (editors) (1988) Glutathione conjugation. Mechanisms and biological significance. London: Academic Press.
35. Hayes, J. D and Wolf, C. R (1988) Role of glutathione transferase in drug resistance. In Glutathione conjugation. Mechanisms and biological significance, edited by H. Sies and B. Ketterer, London: Academic Press (pp. 315).
36. Kelley, S. L., Basu, A , Teicher, B. A , Hacker, M. P., Harner, D. H. and Lazo J. S. (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241, 1813-1815.
37. Buller, A. L., Clapper, M. L. and Tew, K. D. (1987) Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol. Pharmacol. 31, 575-578.
38. Yang, W. Z., Begleiter, A., Johnston, J. B., Israels, L. G. and Mowat, M. R. A. (1992) Role of glutathione and glutathione S-transferase in chlorambucil resistance. Mol. Pharmacol. 41, 625-630.
39. Bank, B. B., Kanganis, D., Liebes, L. F. and Silber, R. (1989) Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes. Cancer Res. 49, 554-559.
40. Begleiter, A., Goldenberg, G. J., Anhalt, C. D., Lee, K., Mowat, M. R. A. Israels, L. G. and Johnston, J. B. (1991) Mechanisms of resistance to chlorambucil in chronic lymphocytic leukemia. Leuk. Res. 15, 1019-1027.
41. Torres-Garcia, S. J., Cousineau, L., Caplan, S. and Panasci, L. (1989) Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem. Pharmacol. 38, 3122-3123.
42. Geleziunas, R., McQuillan, A., Malapetsa, A., Hutchinson, M., Kopriva, D., Wainberg, M. A., Hiscott, J., Bramson, J. and Panasci, L. (1991) Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J. Natl. Cancer Inst. 83, 557-564.
43. Silber, R., Farber, C. M., Papadopoulos, E., Nevrla, D., Liebes, L., Brack, M., Brown, R. and Canellakis, Z. N. (1992) Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 80, 2038-2043.
44. Ferraris, A. M., Rolfo, M., Mangerini, R and Gaetani, G. F. (1994) Increased glutathione in chronic lymphocytic leukemia lymphocytes. Amer J. Hematol. 47, 237-238.
45. Schisselbauer, J. C., Silber, R , Papadopoulos, E., Abrams, K., LaCreta, F. P. and Tew, K. D. (1990) Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 50, 3562-3568.
46. Marie, J. P., Simonin, G., Legrand, O., Delmer, A, Faussat, A. M., Lewis, A. D., Sikic, B I. and Zittoun, R. (1995) Glutathione-S-transferases Pi, Alpha, Mu and mdrl rnRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 9, 1742-1747.
47. Fisher, D. E. (1994) Apoptosis in cancer therapy: Crossing the threshold Cell 78, 539-542.
48. Strasser, A., Harris, A. W., Jacks, T. and Cory, S. (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79, 329-339.
49. Cotter, T. G., Lennon, S. V., Glynn, J. G. and Martin, S. J. (1990) Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res. 10, 1153-1159.
50. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. and Jacks, T. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
51. Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T. and Saito, H. (1994) The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84, 3158-3165.
52. Reed, J. C. (1994) Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124, 1-6.
53. Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619.
54. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G. and Thompson, C. B. (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608.
55. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A. and Yuan, J. (1993) Induction of apoptosis in fibroblasts by IL-1Beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-. Cell 75, 653-660.
56. Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P. and Green, D. R. (1992) Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257, 212-214.
57. Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W. and Greenberg, A. H. (1994) Premature p34cdc2 activation required for apoptosis. Science 263, 1143-1145.
58. Hickman, J. A. (1992) Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 11, 121-139.
59. Savill, J., Fadok, V., Henson, P. and Haslett, C. (1993) Phagocyte recognition of cells undergoing apoptosis. Immunology Today 14, 131-136.
60. Begleiter, A., Lee, K., Israels, L. G., Mowat, M. R. A. and Johnston, J. B. (1994) Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 8 Suppl 1, S103-S106
61. Robertson, L. E., Chubb, S , Meyn, R. E., Story, M., Ford, R., Hittelman, W. N. and Plunkett, W (1993) Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 81, 143-150.
62. Zinzani, P. L., Buzzi, M., Farabegoli, P., Tosi, P. Fortuna, A., Visani, G., Martinelli, G., Zaccaria, A. and Tura, S. (1994) Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells. Leuk. Lymphoma 13, 95-97.
63. Johnston, J. B., Lee, K., Verburg, L., Blondal, J. Mowac, M R A., Israels, L. G. and Begleiter, A. (1992) Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2′-deoxycoformycin. Leuk. Res. 16, 781-788.
64. Lee, S., Christakos, S. and Small, M. B. (1993) Apoptosis and signal transduction: Clues to a molecular mechanism. Current Opinion in Cell Biology 5, 286-291.
65. Fisher, T C., Milner, A E., Gregory, C. D., Jackman, A. L., Aherne, G. W., Hartley, J. A., Dive, C. and Hickman, J. A. (1993) Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 53, 3321-3326.
66. Miyashita, T. and Reed, J. C. (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 81, 151-157.
67. Walton, M. I., Whysons, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J and Kohn, K. W. (1993) Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53, 1853-1861.
68. Campos, L., Rouault, J. P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J. P. and Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091-3096.
69. Miyashita, T , Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B. and Reed, J. C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805.
70. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. and Craig, R. W. (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. U.S.A. 90, 3516-3520.
71. Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B. and Korsmeyer, S. J. (1995) Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80, 285-291.
72. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A. and Reed, J. C. (1995) Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell 80, 279-284.
73. Miyashita, T. and Reed, J. C (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
74. Kanada, M., Delia, D . Aiello, A., Stadtmauer, E. and Reed, J. C. (1993) bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82, 1820-1828.
75. Adachi, M., Tefferi, A., Greipp, P. R., Kipps, T. J. and Tsujimoto, Y. (1990) Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J. Exp. Med. 171, 559-564.
76. Prokocimer, M. and Rotter, V. (1994) Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84, 2391-2411.
77. Levine, A. J., Momand, J. and Finlay, C. A. (1991) The p53 tumour suppressor gene. Nature 351, 453-456.
78. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M. and Dalla-Favera, R. (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia Proc. Natl Acad. Sci. U.S.A. 88, 5413-5417.
79. El-Rouby, S., Thomas. A., Costin, D., Rosenberg, C R., Potmesil, M., Silber, R and Newcomb, E. W. (1993) p53 Gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82, 3452-3459.
80. Wattel, E., Preudhomme, C , Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. and Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148-3157.
81. Yonish Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.
82. Fritsche, M., Haessler, C and Brandner, G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307-318.
83. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169-1174
84. Smith, M. L., Chen, I., Zhan, Q., Bae, I., Chen, C., Gilmer, T. M., Kastan, M. B., O'Connor, P. M. and Fornace, A. J., Jr. (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1380.
85. Selvakumaran, M., Lin, H. K , Miyashita, T., Wang, H. G., Krajewski, S., Reed, J. C., Hoffman, B. and Liebermann, D. (1994) Immediate early up-regulation of bax expression by p53 but not TGFBeta1: A paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798.
86. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L. and Wyllie, A. H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852.
87. Fisher, D. E., Bodis, S., Lowe, S., Takemoto, C., Housman, D. and Jacks, T. (1994) Restoration of apoptosis in p53 deficient tumor cells. Blood 84(Suppl). 111a
88. Barak, Y., Juven, T , Haffner, R. and Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461-468.
89. Price, B. D. and Park, S. J. (1994) DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res. 54, 896-899.
90. Mosner, J. and Deppert, W. (1994) p53 and mdm2 are expressed independently during cellular proliferation. Oncogene 9, 3321-3328.
91. Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
92. Gaidano, G., Newcomb, E. W., Gong, J Z , Tassi, V., Neri, A., Cortelezzi, A., Calori, R., Baldini, L. and Dalla-Favera, R. (1994) Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Amer. J. Pathol. 144, 1312-1319.
93. Doehner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P. R., Poustka, A., Hunstein, W. and Lichter, P. (1995) p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood 85, 1580-1589.
94. Huang, Y. Q., Raphael, B., Buchbinder, A., Li, J. J., Zhang, W. G. and Friedman-Kien, A. E. (1994) Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia. Amer. J. Hematol., 47, 139-141